文献速递肝胆胰外科

KRAS变异亚型与手术切除肝内胆管癌生存及复发的关联

Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
PubMed 文献 · JAMA Surg · 2022-01-01

该单中心队列研究纳入2009年1月至2016年12月在中国一家医院接受根治性切除的1024例肝内胆管癌患者,采用全外显子组测序、靶向测序和Sanger测序鉴定KRAS变异。127例(12.4%)检出14种KRAS体细胞变异亚型,G12D最常见(55/127,43.3%)。多因素分析显示G12 KRAS变异(而非非G12变异)与更差的总生存(HR 1.69,95%CI 1.31-2.18,P<.001)和无病生存(HR 1.47,95%CI 1.16-1.88,P=.002)独立相关;G12V亚型预后最差(OS HR 3.05,95%CI 1.94-4.79,P<.001;DFS HR 1.79,95%CI 1.13-2.85,P=.01)。

要点

  • 1024例手术切除ICC中127例(12.4%)检出KRAS变异,G12D最常见(43.3%)。
  • G12 KRAS变异独立关联更差OS(HR 1.69)和DFS(HR 1.47),非G12变异无此关联。
  • G12V亚型预后最差,OS HR 3.05、DFS HR 1.79。

核心结论

  • G12 KRAS变异(而非非G12变异)与手术切除肝内胆管癌更差生存和更高复发风险相关,G12V亚型结局最差。

研究设计与样本

  • 单中心队列研究,纳入2009年1月至2016年12月在中国一家医院接受根治性切除的1024例肝内胆管癌患者,采用全外显子组测序、靶向测序和Sanger测序鉴定KRAS变异,数据分析时间为2020年4月至2021年1月。

主要发现

  • 127例(12.4%)检出14种KRAS体细胞变异亚型,G12D占55/127(43.3%),G12V占25/127(19.7%),G12C占9/127(7.1%),G13D占8/127(6.3%)。
  • KRAS变异患者较野生型更常见CA19-9升高(92/127[72.4%] vs 546/897[60.9%],P=.01)和γ-谷氨酰转移酶升高(72/127[56.7%] vs 420/897[46.8%],P=.04)。
  • 多因素分析显示G12 KRAS变异独立关联更差OS(HR 1.69,95%CI 1.31-2.18,P<.001)和DFS(HR 1.47,95%CI 1.16-1.88,P=.002),非G12变异无此独立关联。
  • G12V亚型预后最差:OS HR 3.05(95%CI 1.94-4.79,P<.001),DFS HR 1.79(95%CI 1.13-2.85,P=.01)。

关键数值与推荐

  • KRAS变异亚型分布:G12D 43.3%(55/127)、G12V 19.7%(25/127)、G12C 7.1%(9/127)、G13D 6.3%(8/127)。
  • G12 KRAS变异 vs 野生型:OS HR 1.69(95%CI 1.31-2.18,P<.001),DFS HR 1.47(95%CI 1.16-1.88,P=.002)。
  • G12V亚型:OS HR 3.05(95%CI 1.94-4.79,P<.001),DFS HR 1.79(95%CI 1.13-2.85,P=.01)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: KRAS variants are associated with tumor progression; however, the prevalence of KRAS variant subtypes and their association with survival and recurrence in patients with intrahepatic cholangiocarcinoma (ICC) after curative resection are largely unknown. OBJECTIVE: To explore the prognostic association of KRAS variant subtypes with survival and recurrence in patients with ICC. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, patients who underwent curative resection for ICC from January 2009 through December 2016 at a single hospital in China were recruited, and whole-exome sequencing, targeted sequencing, and Sanger sequencing were performed to identify KRAS variants. Kaplan-Meier and log-rank tests were used to compare overall survival (OS) and disease-free survival (DFS). Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. Data were analyzed from April 2020 to January 2021. INTERVENTIONS: Hepatectomy in patients with ICC. MAIN OUTCOMES AND MEASURES: The association of KRAS variant subtypes with OS and DFS. RESULTS: Of 1024 included patients with ICC, 621 (60.6%) were male, and the mean (SD) age was 59.2 (10.2) years. A total of 14 different subtypes of KRAS somatic variants affecting 127 patients (12.4%) were identified. G12D was the most frequent allele in this cohort, accounting for 55 of 127 identified KRAS variants (43.3%), followed by G12V (25 [19.7%]), G12C (9 [7.1%]), and G13D (8 [6.3%]). Compared with patients with wild-type KRAS, patients with variant KRAS were more likely to have high levels of carbohydrate antigen 19-9 (92 of 127 [72.4%] vs 546 of 897 [60.9%]; P = .01) and γ-glutamyltransferase (72 of 127 [56.7%] vs 420 of 897 [46.8%]; P = .04). Multivariable analysis revealed that G12 KRAS variants but not non-G12 KRAS variants were independently associated with worse OS (hazard ratio [HR], 1.69; 95% CI, 1.31-2.18; P < .001) and DFS (HR, 1.47; 95% CI, 1.16-1.88; P = .002). Among the patients with G12 KRAS variants, the G12V KRAS variant was the strongest prognostic determinant for the worst OS (HR, 3.05; 95% CI, 1.94-4.79; P < .001) and DFS (HR, 1.79; 95% CI, 1.13-2.85; P = .01). CONCLUSIONS AND RELEVANCE: In this cohort study, the distribution of KRAS variant subtypes was characterized in a large cohort of patients with ICC from China. The presence of G12 KRAS variants but not non-G12 KRAS variants was associated with worse survival and increased risk of recurrence. Patients with the G12V variant exhibited the worst outcomes in the whole cohort.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Zhou SL, Xin HY, Sun RQ, et al. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surg. 2022. PMID: 34730772. doi:10.1001/jamasurg.2021.5679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。